Omega-3 Fatty Acids in Elderly Patients With Acute Myocardial Infarction

Conditions

Myocardial Infarction, Heart Failure, Myocardial Revascularization, Atrial Fibrillation

Keywords

Fatty Acids, Omega-3, Aged, Myocardial Infarction

Brief summary

The aim of the present study is to investigate the possible effects of supplementation with 1.8 g/day of n-3 polyunsaturated fatty acids on cardiovascular morbidity and mortality during a follow-up period of 2 years in an elderly population after having experienced an acute myocardial infarction. The hypothesis is that this supplementation on top of modern therapy will reduce the combined cardiovascular end-point of death, non-fatal myocardial infarction, stroke, revascularizations or hospitalization for new or worsened heart failure with at least 30%.

Chiva-Blanch G, Bratseth V, Laake K, Arnesen H, Solheim S, Schmidt EB, Badimon L, Seljeflot I.

2021-10-208 citations

10.1016/j.clnu.2021.10.007

Biomarkers of ageing and cardiac remodeling are associated with atrial fibrillation

Are A. Kalstad, Peder L. Myhre, K Laake, Trine B. Opstad, Arnljot Tveit et al. (8 authors)

Scandinavian Cardiovascular Journal2021-03-0222 citations

10.1080/14017431.2021.1889653

Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction

Are A. Kalstad, Peder L. Myhre, K Laake, Sjur Hansen Tveit, Erik Berg Schmidt et al. (13 authors)

Circulation2020-11-15288 citations

10.1161/circulationaha.120.052209

Leukocyte telomere length and serum polyunsaturated fatty acids, dietary habits, cardiovascular risk factors and features of myocardial infarction in elderly patients.

Kalstad AA, Tveit S, Myhre PL, Laake K, Opstad TB, Tveit A, Schmidt EB, Solheim S, Arnesen H, Seljeflot I.

2019-12-2716 citations

10.1186/s12877-019-1383-9

Effects of omega 3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study

K Laake, Peder L. Myhre, Linn Marie Nordby, Ingebjørg Seljeflot, Michael Abdelnoor et al. (9 authors)

BMC Geriatrics2014-06-1331 citations

10.1186/1471-2318-14-74

Interventions

DRUGPikasol

Pikasol®, 3 capsules (1.8 g EPA+DHA)/day

OTHERCorn oil

Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

70 Years to 82 Years

Healthy volunteers

No

Inclusion criteria

* Patients with acute myocardial infarction discharged from hospital alive

Exclusion criteria

* Being part of another randomized trial * Documented intolerance for omega-3 fatty acids * Additional disease state that is thought to be incompatible with compliance to the study drugs * Additional disease state thought to reduce survival for the follow-up time of 2 years

Design outcomes

Primary

Measure	Time frame
Combined total mortality, first event of non-fatal myocardial infarction, stroke, revascularization or hospital admission for new or worsened heart failure.	24months

Secondary

Measure	Time frame
Occurence of new onset atrial fibrillation	24months

Countries

Norway

Outcome results

None listed